Peritumoral injection of recombinant human interleukin 1 (3 (IL 1(3) in mice transplanted subcutaneously with Friend erythroleukemia cells (FLC) resulted in a marked increase in survival time and inhibition of metastatic tumor growth in liver and spleen . In contrast, IL-2 treatment alone did not significantly inhibit the development of FLC metastases . A synergistic antitumor effect was observed after combined IL-1/11r2 therapy of these mice. The antitumor action of IL1/IL2 treatment was abolished or markedly reduced in mice treated with antibodies to CD4 or CD8 antigens, whereas antibodies to asialo-GM, were ineffective . A clear-cut increase in the percentage of CD4+ cells was observed in the spleens of cytokine-treated mice on days 17 and 23 . On day 23 of rytokine therapy, CD8+ cells were increased in both spleens and lymph nodes . On day 17, infiltrates of host-reactive cells (i.e., lymphocytes, granulocytes, and monocytes) were observed in both spleen and liver from FLC-injected mice treated with IL-1/IL-2, in association with tumor cells. On days 17 and 23, spleen cells and cells recovered from mesenteric lymph nodes of IL1/IL2-treated mice exerted a potent antitumor effect as determined by Winn assay experiments. This antitumor activity was abolished by preincubation of spleen cells with anti-CD8 antibody, but not by treatment with antibodies to asialo-GMI ; antibodies to CD4 exerted only a slight effect . Combined IL1/IL2 therapy was more effective on established (i.e., 6-7-d) FLC tumors than on early (i.e., 1-d) tumor-transplanted mice . IIr1/IL2 treatments were also highly effective in increasing survival time of mice from which the subcutaneous primary tumors were excised 7 d after FLC injection . These data indicate that in mice injected with FLC, the antitumor effects of IL-1/IL-2 are mediated by CD4+ and CD8+ cells (but not NK cells), and suggest that this combined cytokine treatment may be effective against established metastatic tumors. R ecent data indicate that the combined treatment oftumorbearing animals with multiple cytokines results in a more potent antitumor effect than single cytokine therapy (1-7), thus suggesting that combined cytokine therapy represents an interesting approach to the treatment of some human cancers. In the present study, we have investigated the effects and antitumor mechanisms of combined treatment with ILA and IL2 in mice transplanted with highly malignant Friend erythroleukemia cells (FLC), 1 which metastasize to the liver and the spleen (8) .
Peritumoral injection of recombinant human interleukin 1 (3 (IL 1(3) in mice transplanted subcutaneously with Friend erythroleukemia cells (FLC) resulted in a marked increase in survival time and inhibition of metastatic tumor growth in liver and spleen . In contrast, IL-2 treatment alone did not significantly inhibit the development of FLC metastases . A synergistic antitumor effect was observed after combined IL-1/11r2 therapy of these mice. The antitumor action of IL1/IL2 treatment was abolished or markedly reduced in mice treated with antibodies to CD4 or CD8 antigens, whereas antibodies to asialo-GM, were ineffective . A clear-cut increase in the percentage of CD4+ cells was observed in the spleens of cytokine-treated mice on days 17 and 23 . On day 23 of rytokine therapy, CD8+ cells were increased in both spleens and lymph nodes . On day 17, infiltrates of host-reactive cells (i.e., lymphocytes, granulocytes, and monocytes) were observed in both spleen and liver from FLC-injected mice treated with IL-1/IL-2, in association with tumor cells. On days 17 and 23, spleen cells and cells recovered from mesenteric lymph nodes of IL1/IL2-treated mice exerted a potent antitumor effect as determined by Winn assay experiments. This antitumor activity was abolished by preincubation of spleen cells with anti-CD8 antibody, but not by treatment with antibodies to asialo-GMI ; antibodies to CD4 exerted only a slight effect . Combined IL1/IL2 therapy was more effective on established (i.e., 6-7-d) FLC tumors than on early (i.e., 1-d) tumor-transplanted mice . IIr1/IL2 treatments were also highly effective in increasing survival time of mice from which the subcutaneous primary tumors were excised 7 d after FLC injection . These data indicate that in mice injected with FLC, the antitumor effects of IL-1/IL-2 are mediated by CD4+ and CD8+ cells (but not NK cells), and suggest that this combined cytokine treatment may be effective against established metastatic tumors.
R ecent data indicate that the combined treatment oftumorbearing animals with multiple cytokines results in a more potent antitumor effect than single cytokine therapy (1-7), thus suggesting that combined cytokine therapy represents an interesting approach to the treatment of some human cancers. In the present study, we have investigated the effects and antitumor mechanisms of combined treatment with ILA and IL2 in mice transplanted with highly malignant Friend erythroleukemia cells (FLC), 1 which metastasize to the liver and the spleen (8) . ' A bbreviations used in this paper . FLC, Friend erythroleukemia cells ; LAK, lymphokine-activated killer.
IL1, a cytokine mainly produced by stimulated monocytes/macrophages, promotes T and B lymphocyte activation and induces a wide range of biological effects in vitro and in vivo (9) (10) (11) . However, little data are available on the antitumor effects of IIA in experimental tumors (12) (13) (14) (15) (16) (17) . In contrast, a number of studies have reported that IIA exerts marked antitumor effects in both experimental animals and cancer patients (18) (19) (20) . It has been suggested that the antitumor effects of IIA are mediated by the in vivo generation of lymphokine-activated killer (LAK) cells (21, 22) , although a direct correlation has not been shown between the in vivo antitumor efficacy of IIA and the in vitro cytolytic activity of LAK cells against a variety of mouse tumors (17, 23) .
In past studies, we have used mice transplanted with highly metastatic FLC to investigate the antitumor effects of IFNca/(3 (24-28), TNT-tx (29, 30) , ILA (16, 17) , and 11,2 (17) . Peritumoral injections of IL-2, alone or in combination with LAK cells, did not inhibit the development of spleen or liver metastases, although some inhibition of the primary subcutaneous FLC tumor was observed (17) . In contrast, injection of 11,10 resulted in a marked reduction of tumor growth and in an increased survival time, as compared with control mice (16, 17) . In preliminary experiments, we observed that the combined treatment with 1171 and IL2 of mice transplanted with FLC resulted in an antitumor effect greater than that observed with either cytokine alone (17) . In the present study, we have described the synergistic antitumor effects of the combined IL1/IL2 treatment in mice injected with FLC and we have characterized the host mechanisms involved in this antitumor response. Furthermore, we provide evidence that this combined cytokine treatment is markedly effective in inducing the regression of established liver and spleen metastases .
Materials and Methods
Mice. 6-8-wk-old male DBA/2 mice were obtained from Charles River Breeding Laboratories (Italia Calco, Italy) . Nude mice were kept under specific germ-free conditions using sterile filters.
Tumor Cells. IFN-tx//3-sensitive 745 and IFN-a/a-resistant 3C1-8 PLC (31) were serially passaged intraperitoneally in syngeneic DBA/2 mice (in vivo passaged FLC) . These FLC are highly metastatic to the spleen and to the liver (8) and exhibited a specific membrane glycoprotein pattern as compared with that of the nonmetastatic in vitro passaged FLC (32) .
11,2,11-1/3, and Control Preparations. Human rIIL2 (sp act, 3 x 106 U/mg of protein) (Hoffmann-La Roche, Inc., Nutley, NJ) was obtained through the National Cancer Institute (Dr. Michael J. Hawkins, Chief of the Investigational Drug Branch). Electrophoretically pure human rI1,10 (mature fragment 117-269, expressed in Escherichia coli) had a specific activity of N5 x 108 half-maximal U/mg of protein in the D10.G4.1 proliferation assay (33) . IL10 was provided by Sclavo (Siena and Cassina de Pecchi, Italy), through the courtesy of Dr. D. Boraschi (Centro Ricerche Sclavo, Siena) . Cytokines were diluted in physiologic solution (153 mM NaCl); endotoxin contamination was <0 .1 ng/mg as determined by limulus amoebocyte lysate assay. Control preparations consisted of physiologic solution unless otherwise stated.
Antibodies to Asialo-GM,, CD4, and CD8. Anti-asialo-GM, rabbit antibody (10 mg/ml) (34, 35) was purchased from Wako Chemicals (Neuss 1, FRG) . DBA/2 spleen cells taken from mice injected three times intravenously with 5 0,ug of antibody to asialo-GM, (days 0, +7, +11) showed no significant NK cell cytotoxicity for mouse YAC cells in vitro.
The rat hybridoma cell mAb GK1-5 (36, 37) producing mAb to CD4 (L3T4) was provided by Prof. G. Forni (Institute of Microbiology, University of Turin, Turin, Italy) . Hybridoma cells were passaged intraperitoneally in BALB/c nude mice in our laboratory. The Ig fraction of ascitic fluids was separated by ammonium sulfate precipitation. The protein concentration was N10 mg/ml. Intravenous injection of DBA/2 mice with 500 NAg of the anti-CD4 Ig resulted in complete depletion of CD4* spleen cells, 6-9 d after inoculation of antibody, as determined by flow cytometric analysis
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Antitumor Effects of Interleukin 1 and 2 using a FITC-labeled anti-CD4 mAb (Becton Dickinson & Co ., Mountain View, CA). The Ig fraction of ascitic fluids from the rat hybridoma cell mAb 53-6.7 (38) producing mAb to CD8 (Lyt-2) was separated by ammonium sulfate precipitation .
Intraperitoneal injection ofDBA/2 mice with 1 mg of anti-CD8 Ig resulted in complete depletion of CD8' spleen and lymph nodes cells when tested 15 d thereafter by flow cytometric analysis using a FITC-labeled anti-CD8 mAb.
Silica . Silica particles (average size <5 um) were provided through the generosity of Dr. K. R6bock (Steinkohlenbergbauverein, Essen-Krey, FRG) . Mice were injected intravenously with 5 mg of silica particles. This dose had been shown to be effective in destroying peritoneal macrophages after intraperitoneal injection.
Flow Cytometric Analysis ofHost Cellsfrom FLC-injected Mice. The phenotypes of lymphoid cells present in lymph nodes and spleens o£ animals injected with FLC were evaluated by direct immunofluorescence using specific mAbs .
Spleen and mesenteric lymph nodes were removed aseptically and washed with the hub of a syringe in RPMI 1640 . The cell suspension and spleen or lymph node fragments were then passed through a single layer of 100-gauge nylon mesh, and the cells were Statistical Analyses. Data were analyzed by student's t test . Light Microscopy Studies. Mice were killed by ether. Primary subcutaneous tumors, spleens, and livers were removed, cut into two pieces of -0 .5 cm 3, and fixed in 10% formalin for several days . Fixed tissues were subsequently processed for paraffin embedding, cut into 2-3-pm-thick slices, and stained with hematoxylin and eosin.
Results
Synergistic An titumor E$ect of Combined 11,1 and 11,2 Treatment. Table 1 summarizes the results of five experiments in which DBA/2 mice were injected subcutaneously with different FLC types and subsequently treated with 11,2, IL1, or a combination of both cytokines. In all cases, combined ILl/IL2 treatment resulted in an antitumor effect greater than that observed with either cytokine alone, even though some variability of the antitumor activity was observed . Fig. 1 (A) shows a representative experiment on the synergistic antitumor effect of combined IL1/IL2 treatment. Thus, DBA/2 mice were injected subcutaneously with highly metastatic 3C1-8 FLC and, after 1 d, the mice were treated 6-8-wk-old male DBA/2 mice were injected with different FLC types. 24 h after tumor injection, mice were treated peritumorally (0 .2 ml per mouse, twice a day: approximately 10 am and 6 pm) on days 2, 3, 4, 7, 8, 9, 14, 15, 16, 20, 21 , and 22. IL-1 and IL-2 were injected together in a total 0.2 ml volume . IL-1, 250 ng/treatment ; IL-2, 20,000 U/treatment. Survived mice were killed 100-135 d after FLC injection and were found to be tumor free .
subcutaneously (i.e., peritumorally) with IL 10, IL-2, or a combination of both cytokines . Subcutaneous injection of IL1f3 resulted in marked inhibition of tumor growth (data not shown) and a clear-cut increase in survival time, as compared with control FLC-injected mice (Fig. 1 A) . In agreement with previous findings (17) , subcutaneous treatment with 11,2 alone resulted in some inhibition of tumor growth, but only a slight increase in survival time as compared with control mice was observed . As shown in Fig . 1 (A) , the concomitant treatment with both ILA and 11,2 resulted in a synergistic antitumor effect. On days 8-10, all treated mice in this group developed small FLC tumors, comparable with those of control mice . On day 10, the mean surface area of these tumors was 60.8 ± 5 .0. These IL1/IL2-treated tumors regressed 3-4 wk after tumor cell injection and a few days after treat- 31 5 Ciolli et al .
ment had been discontinued. All control and IL-2-treated mice died with extensive liver and spleen metastases. In contrast, 30% of the I14-treated mice were tumor free 140 d after tumor cell injection . The combined IM/IL-2 treatment resulted in complete regression of the tumor and recovery in 60% of the FLC-injected mice . At death, the IIL1/IIL2-treated mice injected with the in vivo passaged FLC exhibited liver and spleen metastases, indicating that this combined cytokine treatment did not modify the in vivo behavior of FLC . As shown in Fig. 1(B) , combined 11,1/IL2 peritumoral treatment resulted in a slight decrease in body weight as compared with control animals, within 1-2 wk of cytokine administration . However, no toxicity was observed at any time during ILlAL2 treatment .
In vitro treatment of FLC with IL-1 (50 ng/ml), IL-2 (2,000-20,000 U/ml), or a combination of both cytokines did not result in significant inhibition of cell proliferation 1-3 d after cell seeding (data not shown) .
Efficacy o,f11,1/11,2 Treatment in Mice InjectedSubcutaneously with FLC and Treated with Antibodies to CD4, CD8, or AsialoGMi. It was of interest to determine the antitumor effects of Ilr1/IL2 treatment in mice whose immune response was defective because of the injection of antibodies directed against specific cell types. As shown in Table 2 , the antitumor effect of Ilr1/IL2 therapy was completely abrogated in mice treated with anti-CD4 antibody. Injection of anti-CD8 antibody also resulted in a marked reduction of the IL1AL2 antitumor effects. In contrast, treatment with anti-asialo-GM, antibody, which completely inhibited specific NK cell activity, did not significantly affect the antitumor activity of IL1/ IL2 ( Table 2 ). Injection of mice with silica, which has been shown to be toxic for macrophages, partially inhibited the antitumor effects of the IL1/IL2 treatment (data not shown) .
Effects of 11,1/11,2 Treatment on Lymphocyte Subsets in the Spleen and Lymph Nodes ofFLC-injected DRA/2 Mice. IL1/ IL2 treatment of mice injected subcutaneously with FLC resulted in a marked increase in the percentage of CD4+ spleen cells on days 17 and 23 after tumor cell injection (i.e., a twofold and a fivefold increase, respectively) . On these days, a slight increase in the percentage of CD4+ cells was also observed in the mesenteric lymph nodes of Ilr1/IL2-treated mice (data not shown) . Moreover, the flow cytometric analyses of host cells recovered on day 23 from FLC-injected mice revealed a clear-cut increase in the percentage of CD8+ cells in the spleens and lymph nodes of IIr1/IL2-treated mice (i.e., a 12-fold and a twofold increase, respectively) (data not shown) . Generation of Effector Cells Endowed with Potent Antitumor Activity during H,1/1L2 Treatment ofFLC-injected Mice. The livers and spleens of FLC-injected mice were examined by light microscopy at different times after Ilr1/IL2 treatments . On days 10, 14, 17, and 20, the histologic examination of livers and spleens of FLC-injected mice revealed the presence of both tumor cells and infiltrating host cells . Apparent micrometastases were observed in the livers of ILlAL2-treated Table 2 . Effects of Injection of Antibodies to Specific Cell Types on the Antitumor Activity of IL-11IL-2 Treatment 6-8-wk-old male DBA/2 mice were injected subcutaneously with 5 x 106 3C1-8 FLC. Some mice were treated with different antibodies as described in Materials and Methods. 1 d after FLC injection, mice were treated subcutanteously with saline or IL-1 + IL-2 as described in the legend to Fig. 1, on days 1, 2, 3, 7, 8, 9 , 13, 14, and 15 . Surviving mice were killed 120 d after tumor injection and found to be tumor free . 'p < 0.001 . mice on days 10 and 17 . On these days, aliquots of cells recovered from the spleens of IL-1/11,2-treated FLC-injected mice were seeded in medium containing agarose to determine the number of FLC colonies (24) . Values ranging from 1.2 x 104 to 2.5 x 10 5 FLC per spleen were found by counting the FLC colonies grown in agarose, indicating that a consistent number of tumor cells were present in the spleens of ILl/IL2-treated mice. On day 17, infiltrates of host-reactive cells (i .e ., lymphocytes, granulocytes, and monocytes) were clearly observed in both spleen (data not shown) and liver (Fig . 2, B and C) from FLC-injected mice treated with lLl/IL2. At this time, large areas of hemorrhagic tumor necrosis were present within the primary subcutaneous tumors from the treated mice (Fig. 2 E) , and similar host cell infitrates were detected (Fig . 2 F) .
Experiments were then performed to determine whether host cells from cytokine-treated mice might exert some antitumor activity in typical Winn assays . No antitumor activity was found using spleen cells, peritoneal cells, or cells from lymph nodes of mice on day 10 of cytokine therapy (data not shown) . In contrast, a clear-cut antitumor activity was exhibited by host cells recovered from the spleens and lymph nodes of mice on days 17 and 23 of treatment with IL1/IL2 (Table 3 ) . This antitumor activity was abolished by pretreatment of spleen cells with anti-CD8 antibody, but not by preincubation with anti-asialo-GM i antibodies (Fig.  3) . A slight inhibition of tumor growth was observed by treatment of spleen cells with antibodies to CD4 (Fig. 3) .
ILI/IL2 Treatment Is More Effective in Mice with Established FLC Tumors Than in Early Transplanted Mice. The data presented above suggested that IL1AL2 treatment was effective Table 3 . Antitumor Activity of Host Cells Recovered from Cytokine-treated FLC-injected Mice (Winn test) 7-wk-old male DBA/2 mice were injected subcutaneously with 2 x 106 in vivo passaged 3C1-8 FLC. Treatment was as follows: 0.2 ml of either saline or IL-la + IL-2 (250 ng and 20,000 U, respectively) injected twice (i .e ., at approximately 10 am and 6 pm) on days 1, 2, 3, 7, 8, 9, 14, 15, and 16 . On day 17 of tumor growth, pooled cells recovered from each experimental group were mixed with 5 x 104 in vivo passaged FLC and injected subcutaneously into DBA/2 mice . There were six mice in each group. ' The E/T cell ratio was -20:1 . t The E/T cell ratio was -10:1 . Fig . 5 shows the effect of the combined cytokine treatment on the growth of established (i.e., 6-d) FLC tumors . IL1AL 2 treatment resulted in a complete arrest of tumor growth . In this experiment, 30% of the 11,1/11L,2-treated mice exhibited a complete tumor regression and were considered to be tumor free 120 d after FLC injection .
IL1/IL2 Treatment Is Elective as Adjuvant Therapy after Surgery in the Inhibition ofLiver and Spleen Metastases. The experiments described above were performed by treating FLCinjected mice peritumorally. Therefore, it was not possible to distinguish between the effects of cytokines on the primary subcutaneous tumor vs. the effects on metastases. On the other hand, intraperitoneal or intravenous treatments with IL-1/IL-2 of mice injected subcutaneously with FLC were less effective in inhibiting tumor growth and exhibited some toxicity, which was not observed after subcutaneous cytokine treatments (data not shown) .
It was of interest, therefore, to study the antitumor effect of the subcutaneous I171/IL-2 treatment after surgical ablation of the subcutaneous primary tumor. Thus, we excised the established subcutaneous tumors on day 7, when tumor cells had metastasized to the spleen and to the liver of most h E E 400- Figure 5 . Effect of IL 1AL2 treatment on the growth of established FLC subcutaneous tumors. 6-wk-old male DBA/2 mice were injected subcutaneously with 2 x 106 in vivo passaged 3C1-8 FLC. Mice were treated with saline or IIA + 11,2 on day 6 after tumor cell injection . 11,1/IL2 treatments were performed as described in the legend to of the injected mice (data not shown) . On day 9, we treated the mice subcutaneously with ILl/IL2 or a control prepara, tion . As shown in Fig. 6 , the combination of tumor resection and IL1/IL2 therapy resulted in a higher rate of survival as compared with control mice .
The present results indicate that combined IL1AL2 treatment of mice injected subcutaneously with FLC results in a synergistic host-dependent antitumor effect as compared with single cytokine treatment (Table 1 and Fig. 1 ). Synergistic antitumor effects have also been described in a variety of experimental tumors treated with different cytokines (1-7) . In the IM/IL-2 treatment of FLC tumors, it is reasonable to assume that most of the antitumor effect observed is caused by IL10, as IL-2 alone does not significantly increase the survival time of FLC-injected mice . Little information is available on the antitumor effects of IM in mice (11) (12) (13) (14) (15) (16) (17) , and to the best of our knowledge, no data have been published on the antitumor effects of ILA in mice transplanted with highly metastatic tumor cells . We have observed that small tumors initially developed in IA-treated mice and subsequently regressed between the second and third week of treatment .
This tumor regression was more rapid in mice treated with both IL1 and IIr2, resulting in the cure of 10-60% of tumorbearing mice . The fact that IIAO alone or in association with Ilr2 did not exhibit a significant inhibitory effect on the in vitro multiplication of FLC suggests that the IWAL2-induced antitumor effect was likely to be host mediated and not related to direct cytostatic or cytotoxic effects of these cytokines on the tumor cell themselves . In particular, the finding that the 11,1/11,2 antitumor effect was completely abrogated or markedly reduced in mice injected with antibodies to CD4 and CD8 (Table 2) suggests that T cells, particularly T helper and cytotoxic lymphocytes, are involved in the generation of this antitumor response. In contrast, NK cells do not appear to play a relevant role in the antitumor effects of IL1/IIr2, as the injection of antibody to asialoGMt did not significantly affect the antitumor effect of the combined cytokine treatment ( Table 2) .
It is emphasized that, although tumor cells were detected by morphologic and biologic assays in the organs of cytokinetreated mice, some of these mice were cured after IL1/IL 2 therapy, thus suggesting the involvement of potent immune mechanisms. In this regard, the following observations are of interest: (a) an increased percentage of CD4+ and CD8+ cells was detected in the spleens of FLC-injected mice on days 17 and 23 ; (b) at this time, host cell infiltrates (mostly lymphocytes and granulocytes) were clearly detected in situ (i.e., primary subcutaneous tumor, liver, or spleen metastases), in close association with tumor cells, in the spleen, liver (Fig.  2 , B and C), and primary subcutaneous tumor (Fig . 2 E and  F) ; (c) likewise, host cells recovered from the spleens and lymph nodes of these mice exhibited marked antitumor activity as determined by Winn test experiments (Table 3) ; and (d) the antitumor activity of spleen cells was abolished by preincubation with antibodies to CD8 (but not with antibodies to CD4 or asialo-GM,) (Fig. 3) . The finding that the anti-CD4 mAb is highly effective in vivo in abolishing the antitumor effect of the 11,1/11,2 therapy, but is not significantly effective in inhibiting the ability of spleen cells to function in a Winn assay, might be due to the fact that CD4+ cells play a crucial role in the generation process of the antitumor immune response, but they are not directly involved in the cytotoxic effector mechanism . The final effector cells responsible for the tumor regression are likely to be CD8+ cytotoxic T lymphocytes, as suggested by the results of the Winn assay experiments (Fig. 3) .
The finding that the IL1/IIr2 treatment was more effective on established (6-8-d) than on early (1-d) implanted subcutaneous tumors (Fig . 4) is consistent with the observation that some tumor cells were present in the liver and spleen of cytokine-treated mice, before the in situ generation of host immune cells could occur. In fact, at 6-8 d after subcutaneous FLC injection, when 11,1/IL2 therapy was started, FLC micrometastases were already detectable in the spleen and liver of the majority of these mice (data not shown) . In this regard, North et al . (14) have recently reported that IL 1/3 caused regression of the immunogenic SA1 sarcoma, growing subcutaneously in syngeneic mice, when given on days 6-8 of tumor growth, but not when given on days 1-3 . It was thus suggested that the antitumor action of ILA was based on an underlying host-immune response that required some tumor growth to be fully generated. Although the highly metastatic in vivo passaged FLC appeared to be nommmunogemc when injected in DBA/2 mice (8, 17) , the data presented in this article on IWAI,2-treated mice seem to be in agreement with those obtained by North et al . (14) in 11,1-treated mice. It is possible to envisage that injection of FLC primes the host's immune system, which is then markedly amplified by IL 1/IL2 treatment .
The antitumor effect o£ 11,1/11,2 therapy was also observed when the primary tumors were surgically removed (Fig. 6  B) , demonstrating that this combined cytokine treatment can exert antimetastatic effects, which are independent from the effects on the primary tumor. It is reasonable to conclude that knowledge of the host mechanisms operative in the potent antimetastatic effect exerted by combined IIrl/11,2 treatment of established FLC tumors may provide some insights in defining new strategies for more effective combined cytokine therapies in patients with advanced tumors.
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